Drugs / METHYL P-TOLUENESULFONYL-L-ARGININATE
METHYL P-TOLUENESULFONYL-L-ARGININATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03953326 | Apr 2019 → Dec 2020 | breast cancer, leukemia, lymphoma | Penn State University | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | METHYL P-TOLUENESULFONYL-L-ARGININATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL44752 ↗ |
| Known as | L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03953326 ↗ |
| Known as | N1-tosyl-l-arginine methyl ester | ChEMBL registry synonym — accepted as the source's own label CHEMBL44752 ↗ |
| Known as | Tame (pharmaceutical) | ChEMBL registry synonym — accepted as the source's own label CHEMBL44752 ↗ |
| Action | Inhibit | “This nitric oxide inhibitor” NCT03953326 ↗ |
| Modality | Small molecule | — CHEMBL44752 ↗ |